Scenario | Risk of VTE per 10 000 healthy women |
---|---|
Non-contraceptive users and not pregnant | 2 |
CHC containing ethinylestradiol plus levonorgestrel, norgestimate or norethisterone | 5–7 |
CHC containing etonogestrel (ring) and norelgestromin (patch) | 6–12 |
CHC containing ethinylestradiol plus gestodene, desogestrel, drospirenone | 9–12 |
Pregnancy | 29 |
Immediately postpartum | 300–400 |
CHC, combined hormonal contraception; VTE, venous thromboembolism.